Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and more than 100 projects in the pipeline. For more general information about the company, visit our corporate overview section.

In March 2009, Genentech became a wholly-owned member of the Roche Group. As part of their merger agreement, in order to advance the ongoing pursuit of excellence in biotechnology and positively impact more patient lives, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech in South San Francisco serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.

Committed to being a strong and engaged corporate citizen, Genentech supports a wide variety of organizations and initiatives through our corporate giving programs.